Table 2.
Metabolic characteristics of participants
| Patient characteristics | LADA patients with high-titer GADA (n = 19) | LADA patients with low-titer GADA (n = 21) | T2DM (n = 14) |
|---|---|---|---|
| Sex (female/male) | 9/10 | 10/11 | 6/8 |
| Age (years) | 50.8 ± 12.4 | 48.1 ± 11.7 | 53.6 ± 9.5 |
| Duration of disease (months) | 21.0 [7.0–29.0] | 20.0 [8.0–36.0] | 7.0 [4.0–30.0] |
| BMI (kg/m2) | 24.1 ± 3.6 | 24.0 ± 2.8 | 22.4 ± 2.7 |
| FBG (mmol/L) | 7.06 ± 2.03 | 7.10 ± 2.49 | 6.08 ± 1.19 |
| PBG (mmol/L) | 13.84 ± 5.59* | 12.38 ± 4.92 | 10.39 ± 3.13 |
| GADA (U/ml) | 623.4 [532.0–853.6]∆∆ | 70.4 [27.6–86.7] | – |
| HbA1c % (mmol/mol) | 6.6 ± 0.9 (47.09 ± 3.03) | 6.6 ± 1.7 (48.07 ± 1.92) | 6.0 ± 0.5 (45.53 ± 1.02) |
| FCP (pmol/L) | 352.7 [300.4–629.3]** | 451.8 [299.6–594.6]** | 593.3 [542.2–798.3] |
| PCP (pmol/L) | 1359.9 [933.4–1798.1]** | 1578.9 [866.1–2174.0] | 1858.1 [1482.0–2909.6] |
*P < 0.05, compared with T2DM group. **P < 0.01, compared to T2DM. ∆∆P < 0.01, compared to low-titer GADA LADA patients
Data are presented as the median with the 25th–75th percentile in square brackets or as the mean ± standard error of the mean (SEM)
BMI Body mass index, FBG fasting blood glucose, FCP fasting C-peptide, GADA glutamic acid decarboxylase autoantibody, HbA1c glycated hemoglobin, LADA latent autoimmune diabetes in adults, PCP 2-h postprandial C-peptide, PBG 2-h postrandial blood glucose, T2DM type 2 diabetes mellitus